Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PROKIDNEY CORP. (PROK)

ProKidney sets up up to $200 million at-the-market share sale program with Jefferies

Neutral Impact 3 of 5 financing Written later

ProKidney entered into an Open Market Sale Agreement with Jefferies LLC on October 29, 2026, allowing it to sell up to $200 million of Class A common stock from time to time through the agent. Sales depend on the effectiveness of a Form S-3 shelf registration filed the same day, and the company has no obligation to sell any shares, so future share issuance could dilute existing shareholders if sales occur.

Key points

  • Agreement with Jefferies LLC dated October 29, 2026, covers up to $200,000,000 in Class A common stock
  • Jefferies compensation is up to 3.0% of gross offering proceeds, plus reimbursement of specified expenses
  • Sales require the Form S-3 shelf registration filed October 29, 2026 to become effective; the company has no obligation to sell shares

The filing

CompanyPROKIDNEY CORP. (PROK)
Form8-K, current report
Filed with the SECOct 29, 2026, 5:15 PM ET
Accession number0001193125-26-438071

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.